Overview: Lyme Disease Qualitative PCR TestIntroduction: The Lyme Disease Qualitative PCR Test detects Borrelia burgdorferi DNA to diagnose Lyme disease, causing rash or joint pain. Following 2023 IDSA guidelines, it uses PCR for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Lyme disease.
Other Names: Lyme PCR Assay, Borrelia DNA Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Lyme PCR testing began in the 1990s with infectious disease research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Borrelia burgdorferi DNA to diagnose Lyme disease, guides treatment, and evaluates patients with rash or joint pain.
Test Parameters: 1. Borrelia burgdorferi DNA
Pretest Condition: No fasting required. Collect whole blood, CSF, synovial fluid, or saliva. Report history of rash, joint pain, or tick exposure.
Specimen: Whole Blood (EDTA, 2-5 mL), CSF (sterile container, 1-2 mL), Synovial Fluid (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document rash, joint pain, neurological symptoms, or history of tick exposure. Include current medications, especially antibiotics.
Consent: Written consent required, detailing the tests purpose, Lyme disease implications, and risks of sample collection.
Procedural Considerations: Uses PCR to detect Borrelia burgdorferi DNA in various specimens. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for Lyme disease diagnosis.
Factors Affecting Result Accuracy: Improper sample storage or contamination can affect results. Low DNA yield may reduce sensitivity.
Clinical Significance: Positive Borrelia DNA confirms Lyme disease, guiding antibiotic therapy (e.g., doxycycline). Negative results may require serology testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Lyme IgG/IgM immunoblot, ELISA, or Western blot to confirm Lyme disease diagnosis.
Test Limitations: Early infection may yield false negatives; clinical correlation is needed. Sample quality affects sensitivity.
References: IDSA Lyme Disease Guidelines, 2023; Clinical Infectious Diseases, Wormser GP, 2022.
